AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8808861
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 mg as needed, 12 to 24 hours before sexual activity)
Trial: 8808861
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 mg as needed)
Trial: 1442579
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg once daily
Trial: 7031208
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily injections of mixed insulin
Trial: 7031208
Drug: Single-dose insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose insulin regimen
Trial: 30795775
Drug: Nutraceutical combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical combination containing Bifidobacterium longum BB536 and red yeast rice extract (10 mg/day monacolin K)
Trial: 29106031
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of valsartan/amlodipine (80/5 mg)
Trial: 23414938
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg daily
Trial: 21989290
Drug: Booster vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster vaccination with three doses of HepB (CHO) vaccine (20μg each) administered at zero, one, and six months.
Trial: 21989290
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (anti-HBs < 0.1 mIU/mL)
Trial: 14737878
Drug: Capsaicin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (5 mg/mL, 30 microL applied topically)
Trial: 7485814
Drug: Drug (Placebo)
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (Placebo) Consumption
Trial: 1791769
Drug: Once-weekly (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly (17 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Trial: 1791769
Drug: Twice-weekly (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly (34 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Trial: 1791769
Drug: Two years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two years of twice-weekly treatment (9 women)
Trial: 7199806
Drug: Not using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not using oral contraceptives (Control)
Trial: 30043065
Drug: Escitalopram (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (5, 10, 15, or 20 mg/d)
Trial: 26731792
Drug: Riboflavin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (200 mg)
Trial: 26731792
Drug: Beetroot (880
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot (880 mg)
Trial: 20889235
Drug: 20% to
RxNorm normalized name: GLYCERIN 20% TOP GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% to 30% salicylic acid peels every 2 weeks for a total of 4 peels along with 4% hydroquinone cream to both sides of the face twice daily
Trial: 20889235
Drug: 4% hydroquinone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% hydroquinone cream to both sides of the face twice daily
Trial: 15987917
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a monotherapy
Trial: 12814993
Drug: High urinary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High urinary phytoestrogen excretion
Trial: 12814993
Drug: High urinary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High urinary isoflavonoids excretion
Trial: 12814993
Drug: Increasing excretion
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing excretion rate of mammalian lignans
Trial: 10585039
Drug: Milrinone treatment
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone treatment (0.5 microg x kg(‐1) x min(‐1) for 24 hours)
Trial: 10585039
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no milrinone treatment)
Trial: 10585039
Drug: Milrinone treatment
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone treatment
Trial: 8708685
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections (mean dose 133.2 units Dysport)
Trial: 1708046
Drug: Quinapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (20 mg twice a day)
Trial: 6753091
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (Bdp)
Trial: 23711618
Drug: Intramuscular IFNβ-1a
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular IFNβ-1a (30 μg once a week)
Trial: 23711618
Drug: Subcutaneous IFNβ-1b
RxNorm normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IFNβ-1b (250 μg every other day)
Trial: 11532838
Drug: Recurrent victimisation
RxNorm normalized name: Acacia decurrens extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recurrent victimisation in year 8 (reported once or twice)
Trial: 31648374
Drug: Paracetamol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 0.5 g + ibuprofen 200 mg
Trial: 31648374
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and ibuprofen (combined)
Trial: 27177997
Drug: IFNB‐1b 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNB‐1b 500 µg
Trial: 27177997
Drug: IFNB‐1b 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNB‐1b 250 µg
Trial: 27177997
Drug: GA 20
RxNorm normalized name: Potiga 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA 20 mg QD
Trial: 18448227
Drug: Oral B
RxNorm normalized name: bran ORAL BOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B 30 toothbrush
Trial: 14523532
Drug: Oxymetazoline without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline without preservative (Nasivin sanft 0.05% spray)
Trial: 11789002
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment in patients with baseline dyslipidaemia
Trial: 9364291
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg, orally once daily for 3 days)
Trial: 9364291
Drug: Co-amoxiclav (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (10 mg/kg in a 4:1 ratio, orally three times daily for 5-10 days)
Trial: 1539845
Drug: Droperidol 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.075 mg/kg
Trial: 1539845
Drug: Metoclopramide 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.15 mg/kg
Trial: 23870606
Drug: Fluticasone/formoterol (100/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol (100/10 µg BID)
Trial: 23870606
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 µg BID)
Trial: 23870606
Drug: Formoterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (10 µg BID)
Trial: 21655065
Drug: OAL (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAL (omeprazole, amoxicillin, levofloxacin)
Trial: 21655065
Drug: OAL-R (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAL-R (omeprazole, amoxicillin, levofloxacin, rifaximin)
Trial: 15225153
Drug: Standard antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressant medication
Trial: 1955900
Drug: Repeated toxin
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated toxin injections
Trial: 25958474
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with a 637 nm GaAlAs laser, 40 mW, continuous wave, 6.26 J/cm2 per implant, applied daily for 7 days post-surgery
Trial: 23307315
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg BD for three cycles
Trial: 23307315
Drug: Aerial parts
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerial parts of wood betony (AWB) 5 g TDS for three months
Trial: 22238738
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of 6% triphala mouthwash
Trial: 22238738
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml of 0.2% chlorhexidine (active control)
Trial: 18991979
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) supplementation (500 mg/day)
Trial: 15009104
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of calcipotriol ointment once daily and betamethasone dipropionate ointment once daily
Trial: 15009104
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate monotherapy
Trial: 9542675
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole 200 mg twice daily for 7 days, followed by placebo for 7 days (n = 153)
Trial: 9542675
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the morning and oral terbinafine 250 mg in the evening for 14 days (n = 151)
Trial: 8117224
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg oral dose)
Trial: 3403825
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dipyridamole-echocardiography test (0.84 mg/kg body weight over 10 min)
Trial: 29360920
Drug: Doxycycline +
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline + Vitamin K1 cream
Trial: 25604761
Drug: Long-lasting insecticidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-lasting insecticidal net screens (LLIS) with targeted treatment (TT) of breeding sites
Trial: 23754384
Drug: Postextinction administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postextinction administration of L-dopa
Trial: 19261278
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin treatment starting from the first day of controlled ovarian hyperstimulation in 1503 cycles
Trial: 19261278
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in the remaining 922 cycles
Trial: 19205092
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg and Valsartan 160 mg
Trial: 19205092
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg and Felodipine 5 mg
Trial: 17011843
Drug: Topical prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical prednisolone and diclofenac (verum)
Trial: 9596422
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of flumazenil at 0.5 mg/h for 5 hours (CI group)
Trial: 8165850
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of Vi-Liq (27 to 34 months after primary immunization)
Trial: 26021722
Drug: Low-dose capecitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capecitabine (1,000 mg/m² twice daily on days 1 to 14 of every 21 days)
Trial: 26021722
Drug: Approved-dose capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Approved-dose capecitabine (1,250 mg/m² twice daily on days 1 to 14 of every 21 days)
Trial: 15380916
Drug: Glutamine enriched
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine enriched total parenteral nutrition
Trial: 15380916
Drug: Isonitrogenous control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isonitrogenous control solution
Trial: 11449622
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with ifosfamide 1.6 g/m2 (d 1-3) and carboplatin (AUC 4, d1) every three weeks, with 21 patients receiving amifostine 740 mg/m2 d1-3 followed by standard radiation therapy (50.4 Gy percutaneous and high-dose-rate-after-loading for 21 patients, 2 x 5 Gy).
Trial: 11449622
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with ifosfamide and carboplatin.
Trial: 7657052
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose tolerance test (25 g glucose/4 min)
Trial: 28080126
Drug: College course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: College course on terrorism (treatment)
Trial: 28080126
Drug: Treatment classes
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment classes from universities across the United States (Study 2)
Trial: 22591260
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser gingivectomy (940‐nm diode laser, ezlase, Biolase Technology Inc) as an adjunct to nonsurgical periodontal treatment
Trial: 22591260
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment only
Trial: 20032535
Drug: Novel antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel antiviral agents
Trial: 15035683
Drug: Soya milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soya milk (0.44 mg isoflavones/kg body weight)
Trial: 15035683
Drug: Tempeh (0.44
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tempeh (0.44 mg isoflavones/kg body weight)
Trial: 15035683
Drug: Textured vegetable
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Textured vegetable protein (TVP) (0.44 mg isoflavones/kg body weight)
Trial: 9551030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription by specialists
Trial: 9551030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription by general practitioners
Trial: 9551030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription for elderly females by specialists
Trial: 9551030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription for elderly females by general practitioners
Trial: 9551030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription for elderly males by specialists
Trial: 9551030
Drug: Warfarin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin prescription for elderly males by general practitioners
Trial: 1782954
Drug: Warfarin withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin withdrawal (sudden or gradual)
Trial: 1782954
Drug: Warfarin withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin withdrawal
Trial: 6784849
Drug: Radical mastectomy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical mastectomy followed by adjuvant chemotherapy (CMF: cyclophosphamide, methotrexate, fluorouracil)
Trial: 30791944
Drug: Oxytocin-enhanced motivational
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin-enhanced motivational interviewing group therapy (MIGT)
Trial: 30791944
Drug: Placebo-enhanced motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-enhanced motivational interviewing group therapy (MIGT)
Trial: 26024940
Drug: Oral Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tranexamic Acid (TA)
Trial: 24418284
Drug: Low-dose dynamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dynamic CT with iterative reconstruction (ASIR) at 100 kV, 40% ASIR, 480 mg I/kg contrast
Trial: 24418284
Drug: Conventional dynamic
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dynamic CT without ASIR at 120 kV, 0% ASIR, 600 mg I/kg contrast
Trial: 10505156
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin 100 mg/m2, bleomycin 15 U/m2, and 5-fluorouracil 1000 mg/m2/day for 1-3 cycles followed by radiotherapy.
Trial: 10505156
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with methotrexate 50 mg/m2 (1-6 weekly injections) followed by radiotherapy.
Trial: 10505156
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin, bleomycin, and 5-fluorouracil followed by radiotherapy.
Trial: 8867255
Drug: Mildly noxious
RxNorm normalized name: SIMPLYTHICK GEL ORAL MILDLY THICK 6GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mildly noxious constant current transdermal electrical stimulation
Trial: 1533167
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with 0.375% bupivacaine plus sufentanil, 1:200,000 (5 micrograms/mL) and intraoperative GA with midazolam/N2O
Trial: 4083810
Drug: Traditional method
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional method of preoperative skin preparation (routine shaving with cetrimide and chlorhexidine in alcohol)
Trial: 23661044
Drug: Topical MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical MMC (0.2 mg/mL for 3 min)
Trial: 17228349
Drug: Plant sterol
RxNorm normalized name: plant sterol complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol margarine (2 g of plant sterols daily)
Trial: 17228349
Drug: Stanol-enriched margarine
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanol-enriched margarine (2 g of stanols daily)
Trial: 3003715
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine (RRV) MMU 18006, 10^5 plaque-forming units
Trial: 27607861
Drug: Oxytocin challenge
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin challenge test (5 international units/500 mL oxytocin Ringer lactate infused at a rate of 12 mL/h, doubled every 10 minutes until three uterine contractions per 10‐minute interval)
Trial: 26652987
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg perindopril arginine salt
Trial: 26652987
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg perindopril tert-butylamine salt
Trial: 23440570
Drug: darunavir/ritonavir (DRV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir (DRV/r) 800/100 mg
Trial: 23440570
Drug: lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir (LPV/r) 800/200 mg
Trial: 17699280
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor plus candesartan (2 to 12 mg/d)
Trial: 10624998
Drug: Remifentanil 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0 ng/mL
Trial: 10624998
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 ng/mL
Trial: 10624998
Drug: Remifentanil 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 4 ng/mL
Trial: 10624998
Drug: Remifentanil 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 8 ng/mL
Trial: 10624998
Drug: Remifentanil 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 16 ng/mL